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ranulocyte Colony-Stimulating
actor and Stem Cell Factor Improve
ontractile Reserve of the Infarcted Left
entricle Independent of Restoring Muscle Mass
asilde Sesti, PHD,* Sharon L. Hale, BS,* Carolyn Lutzko, PHD,† Robert A. Kloner, MD, PHD*
os Angeles, California
OBJECTIVES We investigated whether granulocyte colony-stimulating factor (G-CSF) and stem cell factor
(SCF) could promote myocardial regeneration after coronary artery occlusion and improve
left ventricular (LV) function.
BACKGROUND Cytokine-induced mobilization of bone marrow stem cells in the heart may represent a
promising strategy for replacing infarcted myocardium.
METHODS Sprague-Dawley rats were subjected to permanent coronary occlusion. A treated group (n 
19) received G-CSF (100 g/kg) and SCF (25 g/kg) subcutaneously, starting 2 h after
surgery and continuing daily for an additional 4 days. Control rats (n  21) received sterile
water. The peripheral blood content in hematopoietic progenitor cells was analyzed.
RESULTS At eight weeks, LV angiograms (rest and dobutamine stress) and histologic analysis were
performed. At rest, LV ejection fraction (LVEF) was 0.45 in controls and 0.52 in treated
hearts (p  0.16). For any infarct size, LVEF was greater in the treated group (p  0.045).
Under dobutamine stress, treated animals had smaller LV end-diastolic and -systolic volumes
(0.37 0.04 ml and 0.16 0.03 ml) versus control animals (0.51 0.05 ml and 0.26 0.04
ml; p  0.026 and 0.048) with a 7% improvement in ejection fraction. Scar thickness was 1.1
 0.1 mm in treated hearts and 1.0  0.1 mm in controls (p  0.36). Scar morphology was
similar in both groups without obvious new muscle in the scar.
CONCLUSIONS Because we did not find evidence of new muscle cells in the infarct area, our conclusion is that
G-CSF and SCF enhanced the LV functional reserve of the heart without replacing scar
tissue. (J Am Coll Cardiol 2005;46:1662–9) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.012Cardiology Foundation
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ione marrow stem cell mobilization induced by cytokines
ay represent a promising strategy for repairing infarcted
yocardium. Several growth factors, including interleukin
IL)-3, IL-8, granulocyte-macrophage colony-stimulating
actor (GM-CSF), granulocyte colony-stimulating factor
G-CSF), and stem cell factor (SCF) have been reported to
obilize hematopoietic precursor cells from the bone mar-
ow (1,2) and stimulate endothelial cell migration and
roliferation (3).
Granulocyte colony-stimulating factor, which is currently
sed therapeutically for the treatment of tumors, is one of
he most studied in the setting of myocardial infarction
MI). Granulocyte colony-stimulating factor stimulates the
roliferation and differentiation of precursor cells commit-
ed to the neutrophil/granulocyte cell type (4). Granulocyte
olony-stimulating factor in combination with SCF was also
ound to mobilize primitive bone marrow cells in splenec-
omized mice (5). Stem cell factor stimulates early pluripo-
From the *Heart Institute, Good Samaritan Hospital, Cardiovascular Division,
eck School of Medicine at the University of Southern California, Los Angeles,
alifornia; and †Children’s Hospital-Los Angeles, Los Angeles, California. This
tudy was funded in part by NHLBI grant 1RO1-HLO73709.p
Manuscript received November 2, 2004; revised manuscript received February 3,
005, accepted February 8, 2005.ent and committed stem cells to form colony-forming units
nd can act synergistically with other growth factors, such as
L-1, IL-3, IL-6, GM-CSF, G-CSF, and erythropoietin to
ncrease the production of hematopoietic cells (6,7). Several
tudies have shown that G-CSF improves cardiac function
nd left ventricular (LV) remodeling after MI (5,8–10).
owever, negative results of recent studies have dampened
esearchers’ enthusiasm and questioned the capacity of
rowth factors to induce regeneration and neovasculariza-
ion of myocardial tissue (11–15). At present, the situation
s controversial. Therefore, more research is necessary to
rovide conclusive answers.
In this study, we investigated whether a combination of
he two hematopoietic growth factors, G-CSF and SCF,
ould result in regeneration of myocardial tissue and
mprovement of LV function after permanent coronary
rtery occlusion in rats.
ETHODS
nimals. Fifty-three Sprague-Dawley female rats (200 to
50 g) were used in this study. All the rats were maintained
n accordance with the policies and guidelines of the
osition of the American Heart Association on research
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November 1, 2005:1662–9 Growth Factors and Heart Contractile Reservenimal use (16) and the Committee on Care and Use of
aboratory Animals of the Institute of Laboratory Animal
esources, National Research Council (Department of
ealth, Education, and Welfare Publication No. 85-230).
ll animal procedures were approved by the Institutional
are and Use Committee at Good Samaritan Hospital.
yocardial infarction. The rats were anesthetized with an
ntraperitoneal injection of 75 mg/kg ketamine and 5 mg/kg
ylazine, shaved, endotracheally intubated, and ventilated
ith a rodent respirator. Under sterile conditions, a left
horacotomy in the fourth intercostal space was performed
fter injection of the nerve blocker bupivicane (0.1 mg/kg)
nto the third through fifth intercostal spaces. The pericar-
ium was removed and the proximal left coronary artery was
igated with a 4-O silk suture, causing permanent coronary
rtery occlusion. The chest was then closed and the rats were
eaned from the respirator and extubated. The animals re-
eived buprenex (0.02 mg/kg) as required for analgesia.
reatment protocol. The rats were randomly divided into
wo groups: treated and control. The treated group received
daily dose of 100 g/kg of recombinant methionyl human
-CSF (Neupogen [filgrastim], Amgen Inc., Thousand
aks, California) and 25 g/kg of recombinant rat SCF
Peprotech Inc., Rocky Hill, New Jersey), subcutaneously,
tarting 2 h after coronary occlusion and continuing for the
ollowing four days (5-day treatment). The control group
eceived an equivalent volume of sterile water.
valuation of hematopoietic progenitors in circulation.
lood samples were collected and assayed before and after
he initiation of growth factor treatment. The blood was
ollected in anticoagulant citrate dextran (Sigma-Aldrich,
t. Louis, Missouri) and the progenitor content in the blood
as measured using a methylcellulose-based progenitor
ssay (17). Whole blood cells were assayed in 1% methyl-
ellulose medium containing recombinant cytokines accord-
ng to the manufacturer’s recommended guidelines
Methocult GF R3774, Stem Cell Technologies, Vancouver,
anada). The samples were plated at half-log dilutions from 1
104 to 3  105 with three plates at each cell concentra-
ion. The colonies were counted on days 10 to 14 of culture,
ith the dilution containing 30 well-separated colonies
Abbreviations and Acronyms
EF  ejection fraction
G-CSF  granulocyte colony-stimulating factor
GM-CSF  granulocyte-macrophage colony-stimulating
factor
IL  interleukin
IS  infarct size
LV  left ventricular/ventricle
MAP  mean arterial pressure
MI  myocardial infarction
RMBF  regional myocardial blood flow
SCF  stem cell factorsed to calculate the progenitor content. mhysiologic assessment of LV function. Left ventricular
unction was assessed eight weeks after induction of isch-
mia. The rats were anesthetized and ventilated as described
arlier. Fluid-filled catheters were inserted into the carotid
rtery and jugular vein. Heart rate and arterial pressures
ere measured through a pressure transducer connected to
he catheter in the carotid artery (ADInstruments, Colorado
prings, Colorado). In order to assess heart function with
tress, dobutamine was given as an infusion at a dose of 10
g/kg/min. Angiograms (with the rat in a lateral position)
ere performed before (rest) and during the infusion of
obutamine (stress) by using a mini C-arm fluoroscopy
ystem (XiScan C-arm Imaging system, Xite Inc., East
indsor, Connecticut). The LV was visualized by an
njection of non-ionic contrast (1.5 ml) via the jugular vein.
he contrast circulates to the right ventricle, lung, and then
V, where images of LV end-diastolic and end-systolic
olumes are obtained as previously described (18,19). The
ngiograms were recorded on a VHS videotape and blindly
nalyzed to measure LV systolic/diastolic volumes and
jection fractions.
egional myocardial blood flow and capillary assessment.
egional myocardial blood flow (RMBF) was measured
sing 1  106 radioactive microspheres labeled with 141Ce
Perkin-Elmer Life Sciences, Boston, Massachusetts). After
0 min of stabilization following the angiograms, the chest
as opened, 0.5 ml of sucrose solution containing the
icrospheres was injected into the LV, and simultaneously,
reference blood sample was withdrawn from the carotid
rtery at a rate of 0.37 ml/min.
In order to identify perfused blood vessels in the infarcted
rea, 0.8 ml of 50% Unisperseblue pigment suspension
Ciba-Geigy, Hawthorne, New York) was injected via the
ugular vein. Seconds later, 2 ml of potassium chloride was
njected into the same vein to stop the heart in diastole. The
ats were deeply anesthetized at the time of the injection.
ostmortem analyses. LV VOLUME. The hearts were ex-
ised and fixed in 10% formalin at a constant intraventric-
lar pressure (11 cm H2O) for 30 min. Postmortem LV
olumes were measured by weighing the empty LV, filling
t with distilled water, and weighing it again. Three mea-
urements were made and averaged.
ISTOLOGIC EVALUATION. The hearts were sliced from
pex to base in four transverse sections, which were weighed
nd photographed. One slice from the middle area was
rocessed for histology; it was embedded in paraffin and
ections were stained with both hematoxylin and eosin and
icrosirius red. The sections stained with picrosirius red
collagenous scar stains red and normal tissue stains yellow)
ere used to calculate infarct size (IS). Various parameters
ere determined by computerized planimetry (SigmaScan
ro, Chicago, Illinois): areas and circumferences of ischemic
nd normally perfused regions, LV cavity area, thickness of the
nfarcted and non-infarcted walls (average of three measure-ents), and the thinnest and thickest regions of the scar.
Mi
t
s
b
w
C
m
r
r
p
b
a
S
w
S
b
t
o
a
c
R
M
t
s
e
w
a
E
f
a
t
e
w
i
g
w
t
t
m
t
H
(
i
t
s
d
i
L
e
g
p
h
0
t
1
i
h
h
r
b
w
0
R
v
E
o
p
e
s
t
E
b
d
s
a
R
c
a
i
0
b
n
w
n
g
H
s
i
e
t
n
t
m
t
t
p
i
b
c
n
o
1664 Sesti et al. JACC Vol. 46, No. 9, 2005
Growth Factors and Heart Contractile Reserve November 1, 2005:1662–9EASUREMENT OF RMBF. Samples from infarcted and non-
nfarcted areas were dissected from the other two sections of
he heart and weighed. The radioactivity of these tissue
amples, together with the radioactivity of the reference
lood sample, was counted in a gamma counter, and RMBF
as calculated (20).
APILLARY DENSITY. Capillary density was evaluated by
icroscopic examination of the slide stained with picrosirius
ed. The number of capillaries per high-power field (400),
ecognized as round or tubular structures containing blue
igment, were counted in the scar area, in the left and right
order zone adjacent to the scar, and in the non-infarcted
rea. Results were expressed as number of capillaries per mm2.
TATISTICS. All data are presented as mean  SEM and
ere analyzed using SAS software (Cary, North Carolina).
tudent t tests were performed to compare discrete values
etween treated and control groups. The relationship be-
ween the size of the infarct and either the ejection fraction
r the end-diastolic/systolic volumes was analyzed using
nalysis of covariance (ANCOVA). Values of p 0.05 were
onsidered statistically significant.
ESULTS
ortality. Ten of the 53 rats used in the study died during
he day of surgery after coronary occlusion. Forty-three rats
urvived surgery and myocardial infarction. Three rats were
xcluded because the hearts did not demonstrate an infarct
hen sacrificed at eight weeks. Data are presented for 40
nimals: 19 treated and 21 control rats.
valuation of progenitor mobilization following growth
actor treatment. A separate group of rats was used to
ssess the mobilization of hematopoietic progenitors into
he periphery following growth factor treatment. In these
xperiments the progenitor content was evaluated in the
hole blood cell fraction and the analysis showed a signif-
cantly higher level of progenitors in the blood following
rowth factor treatment (9.5  105 leukocytes) compared
ith the control group (3.65 105 leukocytes) (p 0.0062;
test). These data demonstrate that the growth factor
reatment regimen used in these studies resulted in the
obilization of hematopoietic progenitors into the blood of
reated animals.
emodynamics. Heart rate and mean arterial pressure
MAP) were measured at eight weeks after myocardial
nfarction. There were no significant differences between
he control and the treated groups at any of the time points
tudied: baseline, before dobutamine infusion (rest), during
obutamine infusion (stress), or before RMBF (after open-
ng the chest) (Table 1).
V dimensions. At rest, the angiographic variables LV
nd-diastolic and LV end-systolic volumes between the two
roups did not differ significantly (Table 1).
Under dobutamine stress, treated hearts manifested im-
rovement in these parameters when compared with control cearts. Left ventricular end-diastolic volume was 0.51 
.05 ml in the control hearts versus 0.37  0.04 ml in the
reated hearts during dobutamine stress (p  0.026) (Fig.
). Left ventricular end-systolic volume was 0.26  0.04 ml
n the control hearts versus 0.16  0.03 ml in the treated
earts during dobutamine (p  0.048) (Fig. 1).
There was also a trend (although non-significant) toward
igher LV ejection fraction (EF) in the animals that
eceived the growth factors compared with control animals,
oth at rest (0.52  0.04 vs. 0.45  0.03, p  0.161) and
ith dobutamine stress (0.58  0.04 vs. 0.54  0.04, p 
.450). The increase was 13% and 7%, respectively.
elationship among IS, EF, and LV dimensions. To
erify a possible direct relationship between IS and either
F or LV end-diastolic/systolic volumes, individual values
f IS in both control and treated groups were analyzed and
lotted against the correspondent EF (Fig. 2) or LV
nd-diastolic and -systolic volumes (Fig. 3). The results
howed that, for any infarct size, EF at rest was greater in
he treated group (p  0.045 by ANCOVA) (Fig. 2).
jection fraction under stress was not significantly different
etween the two groups. The data also indicated that, under
obutamine stress, for any infarct size, treated rats had
maller LV end-diastolic and -systolic volumes (p  0.017
nd p  0.016, by ANCOVA) (Fig. 3).
MBF and capillary density. In both groups, treated and
ontrol, RMBF in the ischemic area (1.21 0.20 ml/min/g
nd 1.35 0.22 ml/min/g, respectively) was lower than that
n the non-ischemic area (2.09 0.32 ml/min/g and 2.48
.34 ml/min/g, respectively), with the RMBF in the scar
eing 58% (control) and 55% (treated) of the RMBF in the
on-ischemic tissue. However, RMBF values in each area
ere similar in the two groups (Table 1).
Capillary density, as a measure of neovascularization, was
ot significantly different between the rats receiving the
rowth factors versus control rats (Table 1).
istology and postmortem volumes. Histologic analysis
howed similar mean IS in the two groups either when
nfarct was expressed as a percentage of area or when
xpressed as a percentage of circumference (Table 1).
Other measurements relative to the scar, such as overall
hickness and the thinnest and the thickest regions, were
ot different between the two groups (Table 1). Scar
hickness was 1.0 0.1 mm in control hearts and 1.1 0.1
m in treated hearts (p  0.358).
The thickness of the non-infarcted LV area instead
ended to be lower in the rats that received growth factor
herapy (1.8  0.1 mm vs. 2.1  0.1 mm).
There were no qualitative differences in histologic ap-
earance of the scars between groups. Specifically, the
nfarct scars were primarily composed of collagen, fibro-
lasts, and a few residual cardiomyocytes along the endo-
ardial edge and sometimes the epicardial edge. There were
o large new patches of cardiac muscle as we had previously
bserved with implantation of neonatal or fetal cardiomyo-
ytes (Fig. 4).
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conditions. During stress, volumes were smaller in the treated group. *p 
0.05 versus control.
*Significantly different between the two groups.
Dob  dobutamine; RMBF  regional myocardial blood flow
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November 1, 2005:1662–9 Growth Factors and Heart Contractile ReserveLeft ventricular cavity areas measured by histology and
V postmortem volumes in the pressure-fixed hearts were
imilar in treated and control animals (Table 1).
ISCUSSION
n this study we investigated whether G-CSF and SCF in
ombination could promote myocardial regeneration and
mprove LV function after coronary artery occlusion in rats.
ur findings show that the beneficial effect of G-CSF 
CF treatment relies on a mechanism that is different from
egeneration of myocardium in the infarct (suggested by
ome investigators to be due to stem cell mobilization).
nder stress, growth factor therapy reduced LV diastolic
nd systolic volumes, with a trend to improved EF without
vidence of new muscle. For any given infarct size, EF was
mproved in the G-CSF and SCF group. Scar morphology,
reated Groups (Mean  SEM)
l Treated
n  19 p Value
.96 262.37  11.56 0.779
.86 247.63  6.58 0.325
2.57 389.21  11.66 0.145
.23 233  11.22 0.373
.5 87.95  4.12 0.868
.54 87.26  4.45 0.814
.98 84.58  4.47 0.901
.58 67.42  4.76 0.299
.03 0.43  0.03 0.404
.03 0.21  0.03 0.152
.03 0.52  0.04 0.161
.05 0.37  0.04 0.026*
.04 0.16  0.03 0.048*
.04 0.58  0.04 0.450
.22 1.21  0.2 0.636
.34 2.09  0.32 0.421
58  6 0.720
2 666  28 0.902
9 325  21 0.568
83  10 0.989
6 731  36 0.925
6 859  59 0.668
0 420  30 0.654
38  2 0.714
.1 1.8  0.1 0.093
.1 1.1  0.1 0.358
.1 0.6  0.1 0.921
.1 1.9  0.1 0.532
36  4 0.763
46  3 0.464
.igure 1. Left ventricular (LV) end-diastolic and systolic volumes in
ontrol (open bars) and treated rats (solid bars) under resting and stressTable 1. Variables in Control and Growth Factor-T
Contro
n  21
Hemodynamics
Heart rate (beats/min)
Baseline 258.29  8
Pre-Dob 236.43  8
Under Dob 363.52  1
Pre-RMBF 246  9
Mean arterial pressure (mm Hg)
Baseline 87.05  3
Pre-Dob 86.05  2
Under Dob 85.24  2
Pre-RMBF 73.62  3
Left ventricular dimensions
Rest
Diastolic volume (ml) 0.47  0
Systolic volume (ml) 0.27  0
Ejection fraction 0.45  0
Stress
Diastolic volume (ml) 0.51  0
Systolic volume (ml) 0.26  0
Ejection fraction 0.54  0
Regional myocardial blood flow
Scar (ml/min/g) 1.35  0
Normal tissue (ml/min/g) 2.48  0
Scar/normal tissue (%) 55  8
Capillaries (/mm2)
Left border zone 672  4
Scar  cells 303  2
Scar 83  7
Right border zone 737  5
Normal tissue 895  5
Postmortem volumes (ml) 440  4
Histology
Cavity area (mm2) 40  3
Septum thickness (mm) 2.1  0
Scar thickness (mm) 1  0
Thinnest scar region (mm) 0.6  0
Thickest scar region (mm) 2  0
Infarct size
% Area 35  3
% Circumference 50  4ize, and thickness were indeed similar in both groups,
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Growth Factors and Heart Contractile Reserve November 1, 2005:1662–9ithout obvious new cardiac muscle growth within the scar.
ecause we did not find evidence of new cardiac muscle cells
n the infarct area, our conclusion is that the combination of
-CSF and SCF enhanced the LV functional reserve of the
eart without replacing scar tissue.
The two growth factors G-CSF and SCF are well known
o promote hematopoiesis (4,21,22). In addition, several
tudies have shown that G-CSF, either by itself or in
ombination with SCF, has beneficial effects in MI (5,8–
0). Orlic et al. (5) showed that bone marrow cells,
obilized by administration of G-CSF and SCF to sple-
ectomized mice, home to the infarcted area, differentiate
nto cardiomyocytes, endothelial, and smooth muscle cells;
romote myocardial repair; and reduce mortality by forming
ascular structures and improving anatomic remodeling and
V function. Kocher et al. (8) demonstrated that injection
f bone marrow-derived endothelial progenitor cells mobi-
ized by recombinant human G-CSF contribute to neovas-
ularization of ischemic myocardium in rats and improve
ardiac function. Minatoguchi et al. (10) suggested that the
mprovement in LV function that they observed in a rabbit
odel of coronary occlusion/reperfusion after G-CSF treat-
ent could be a consequence of the regeneration of myo-
ardial tissue and acceleration of the healing of postinfarc-
ion wounds induced by G-CSF.
However, despite these positive and encouraging results,
here is still controversy surrounding the efficiency of growth
actor therapy compared to cell transplantation for the
herapy of MI. Can these factors really stimulate mobiliza-
ion of bone marrow stem cells and differentiation of these
ells into cardiomyocytes?
Recent reports have demonstrated a limited ability of
ome growth factors to restore cardiac function in infarcted
earts of different animal models (11–15). Terrovitis et al.
11) evaluated the effect of GM-CSF administration in a
igure 2. Correlation between ejection fraction at rest and infarct size,
xpressed as percent of left ventricular area. Ejection fraction, for any
nfarct size, was significantly greater in the treated group (closed circles
nd solid line) than in the control group (open circles and dotted line).
tatistical analysis by analysis of covariance.ig model of MI. They did not see a decrease in infarct size
a
ar an improvement in LV remodeling. Maekawa et al. (12)
nvestigated the influence of GM-CSF (different from
-CSF that we used) induction on post-MI remodeling
fter occlusion of the coronary artery in Wistar rats. They
emonstrated that administration of romurtide, a GM-CSF
nducer, delayed collagen production and promoted both
onocyte recruitment to the infarcted heart and infarct
xpansion, which resulted in aggravation of LV remodeling.
akakibara et al. (13) showed that administration of G-CSF
o mice after MI was not as effective as bone marrow cell
ransplantation for infarct repair. Yano et al. (14) did not
bserve any significant differences in infarct sizes and in LV
ystolic and diastolic properties following administration of
-CSF to rats after MI. Chachques et al. (15) demon-
igure 3. Correlation between left ventricular (LV) end-diastolic (A) and
V end-systolic (B) volumes under stress and infarct size, expressed as
ercent of LV area. Both parameters, LV end-diastolic and LV end-
ystolic volumes, for any infarct size were significantly smaller in treated
nimals (closed circles) than in control animals (open circles). Statistical
nalysis by analysis of covariance.
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November 1, 2005:1662–9 Growth Factors and Heart Contractile Reservetrated that administration of vascular endothelial growth
actor to sheep three weeks after MI induced angiogenesis
ut did not improve LV function or remodeling.
The combination of G-CSF and SCF mobilized hema-
opoietic progenitors into the circulation in our rat model of
I. However, this mobilization did not induce either
egeneration of myocardium in the infarcted area or angio-
enesis. In previous studies involving cell transplantation,
e have shown that it is possible to replace scar with muscle
18,19,23,24). We have demonstrated that fetal and neona-
al cardiomyocytes injected directly into the heart muscle
urvive the infarct, differentiate, develop a muscular supply,
hicken the infarct wall with reduction of cavity area and LV
ilation, and improve EF.
In the present study, the thickness of the scar, the LV
avity area, and the infarct size were similar in both growth
actor-treated and control rats. If there was recruitment of
ells to the infarcted tissue, it should have resulted in an
ncrease in wall thickness of the scar without a correspond-
ng increase in the circumference of the scar. We calculated
nd expressed IS either as a percentage of LV area or as a
ercentage of the LV circumference, and in both cases we
igure 4. Picrosirius red-stained sections of control (A,B) and treated (C,D
agnification 40. (B and D) Higher magnification 200 of the area ind
roups is similar without evidence of newly formed muscle in the treatedid not find any difference between the two groups. Also, in sontrast to our previous studies, which injected fetal or
eonatal cardiomyocytes into the scar in which clear-cut
atches of new muscle could be identified, we did not
dentify new muscle in any of the scars of treated animals in
he present study. The number of capillaries and the blood
ow in the scar tissue were also similar between the rats
eceiving the growth factors versus control rats, indicating
quivalent vascularization.
Administration of growth factors, however, elicited some
eneficial effects. Ejection fraction under resting conditions
hen analyzed in relation to infarct size was significantly
igher in the treated group. There was a trend toward
mprovement in EF by 15% at rest and by 7% under stress
onditions in treated rats compared with untreated rats.
nder dobutamine stress, the treated group had smaller LV
nd-diastolic and LV end-systolic volumes. This was also
rue when correlation analysis was conducted between
olumes and infarct size. These data suggest reduced ven-
ricular dilation of the heart under stress following growth
actor administration. Evaluation of the blood revealed that
here was an increase in hematopoietic progenitor cells after
ve days of treatment with G-CSF SCF. Thus, there was
rts. Muscle cells appear yellow, scar tissue appears red. (A and C) Original
by rectangle in panels A and C, respectively. The morphology in the two
s.) heaome mobilization of bone marrow stem cells into the
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Growth Factors and Heart Contractile Reserve November 1, 2005:1662–9irculation. However, we did not see evidence for myocar-
ial regeneration in the scar, which has been suggested to
ccur with mobilization of stem cells. There was similar scar
orphology in both groups without recruitment of cells to
he infarct area. Our conclusion is that the combination of
-CSF and SCF had some benefits in MI through an
ction on residual myocardium that is as yet unknown.
lthough one possibility is that the infarct stimulated
oming of stem cells to the injured area, we did not
pecifically study this concept. However, it is important to
bserve that homing of stem cells is a time-dependent
rocess, as Murry et al. have demonstrated (25). It is
herefore possible that in our study, early after the treatment
ith G-CSF and SCF and for a relatively short period of
ime, there was some recruitment of stem cells to the heart.
he stem cells may have only been able to survive a brief
eriod of time in the hostile and hypoxic environment of the
nfarct, or perhaps they migrated to other tissues. Rather
han developing new heart muscle, the stem cells may have
eleased humoral factors that favorably affected surrounding
iable myocardium (that is, a paracrine effect). This could
xplain why we did not see new muscle in the scar of treated
ats after eight weeks from the treatment, but did observe an
mprovement in cardiac functional parameters.
It is possible that these beneficial effects might be due to
ome of the growth factor-related signaling systems. It is
nown that G-CSF activates a variety of intracellular
ignaling cascades such as JAK/STAT, Ras-Raf-MAP ki-
ase, and Src family kinase pathways (26). Given the fact
hat the JAK/STAT pathway plays a critical role in the
ardiovascular system, it might be that the beneficial effects
hown in our study are a consequence of the activation of
he JAK/STAT signaling pathway associated with a cyto-
ine receptor. In a recent preliminary report, Harada et al.
27) have shown that G-CSF protects the myocardium
rom apoptotic cell death by activation of the JAK/STAT
athway and induction of the expression of anti-apoptotic
olecules in the heart. This resulted in prevention of
ardiac remodeling after MI. At present, the concept that
-CSF may have worked through this mechanism in our
tudy is speculative; however, it would be an interesting path
o explore in future experiments.
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